Скачать или смотреть Jane Larkindale - What is C-Path doing that is unique in drug development for rare disease?

C-Path Executive Director, Duchenne Regulatory Sciences Consortium, Jane Larkindale, DPhil, discusses C-Path's unique approach in rare disease drug development.

Subscribe to C-Path Now ►►    / criticalpathinstitute  

FOLLOW C-PATH: LinkedIn:   / c-path  
Facebook:   / cpathinstitute  
Twitter: https://twitter.com/CPathInstitute?re

ABOUT C-PATH:
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path US is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.

#CPath #drugdevelopment #DRSC #rarediseases #DuchenneMuscularDystrophy #Duchenne #regulatoryscience #consortium #PatientAdvocacy #FDA #EMA #biomarkers #clinicaltrials #clinicaltrialsimulator #diseaseprogression